Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06108050 | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | PHASE1 | RECRUITING | 177 | — | — | Nov 7, 2023 | May 31, 2028 | Dec 16, 2025 | 10 | United States |
| Arm | Type | Description |
|---|---|---|
| Part A1 Dose Exploration: JZP898 monotherapy | EXPERIMENTAL | - |
| Part A2 Dose Exploration: JZP898 in combination with pembrolizumab | EXPERIMENTAL | - |
| Part B Combination Expansion: JZP898 in combination with pembrolizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| JZP898 | DRUG | Investigational drug monotherapy |
| Pembrolizumab | DRUG | Anti-PD1 antibody |
Inclusion Criteria * Adult ≥ 18 years of age * Histological or cytological diagnosis of advanced or metastatic solid tumor. 1. Previously treated participants with solid tumors that are amenable to CPI therapy (eg. NSCLC, melanoma, HNSCC, RCC, HCC, gastroesophageal carcinomas, UC, or CRC \[MSI-H...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |